

Ichthyosis Focus



Vol. 22, No. 1

A Quarterly Journal for Friends of F.I.R.S.T.

Spring 2003

Recent Advances in Molecular Genetics of Ichthyosis

By Gabriele Richard, M.D.



Ichthyoses and related disorders represent a group of more than 28 distinct disorders with different modes of inheritance and different causes, as outlined in the Spring 2002 issue of the *Ichthyosis*

Focus, "How Much Do You Know About Ichthyosis." All these disorders primarily affect the outermost layer of the skin, the epidermis, and can be summarized as disorders of cornification. The epidermis provides our barrier to the environment. It is a highly specialized epithelium designed to protect the human body from water loss and physical, chemical, and mechanical insults. In order to establish and constantly maintain this barrier, the epidermal cells, known as keratinocytes, undergo a complex, highly organized, and tightly controlled process of changes leading to cornification. During this process, cells migrate to the surface, where they form the horny or cornified layer and ultimately are cast off. The human body sheds approximately 2 billion cells during the course of a day. Under normal conditions, cell proliferation and desquamation are in equilibrium. Any external or internal condition that disturbs this balance is bound to impair the barrier function of the skin, eventually resulting in disease. As indicated by the name 'ichthyosis,' that stems from a Greek root meaning fish, these disorders often are characterized by scaling of the skin. Visible scales are produced by shedding of clumps of 100 to 500 or more cells that stick

together. Scaling is usually associated with thickening of the cornified layer, called 'hyperkeratosis,' due to an increased number of cells produced by the epidermis, a delay in cell shedding, or as in most circumstances, a combination of both mechanisms.

In the last decade, enormous progress has been made in deciphering the molecular causes of inherited skin disorders. Genetic research uncovered over 120 different genes, which, when altered, disturb the normal structure and/or function of the skin and result in disease. Among them are 18 genes causing generalized ichthyosis, 19 genes implicated in palmoplantar keratoderma (the thickening of palms and soles), 4 genes linked to erythrokeratoderma (usually characterized by localized redness and thickening of skin), and 9 genes associated with other disorders such as Darier disease and Hailey-Hailey disease. This article highlights some of the most recent advances in genetic research of autosomal recessive ichthyoses, which already has considerably enhanced our understanding of the disease mechanisms and laid the foundation for molecular diagnoses and future development of new treatment modalities.

Autosomal recessive ichthyoses occur in approximately 1 in 100,000 to 1 in 300,000 individuals. Both genders are affected equally. Most autosomal recessive ichthyoses have been observed worldwide without ethnic clustering, although they are more common in populations with a high degree of blood relations (consanguinity). One of the best-known types is Lamellar Ichthyosis (LI), which manifests at birth. Babies are usually born encased in a tight, shiny covering of hardened skin called colloidion membrane. After shedding, large, dark-

brown scales develop over the entire body. The facial skin is tight and may pull eyelids and lips outward (ectropion and eclabion), which can result in secondary damage to the outer parts of the eyes. Other problems include reduced or absent sweating and heat intolerance as well as skin infections and scarring hair loss. The major gene responsible for LI, *TGMI*, is located on the long arm of chromosome 14 and determines the production of an enzyme called transglutaminase-1. As many as 50% of LI patients carry a small change in the DNA code (mutations) in each of the 2 gene copies of *TGMI*. These mutations lead to reduced or absent enzyme production or diminished enzyme activity. To date, over 50 different mutations have been identified. One mutation (designated 2526A->G) appears to be common among individuals of Northern European descent and likely originates from a German ancestor (founder

continued on page 4

2003 Membership Renewal

Renew your annual membership today, the easy way!

See page 12 for details.

Copyright © 2003
by the Foundation for
Ichthyosis & Related Skin
Types

Ichthyosis Focus is published
quarterly by the Foundation for
Ichthyosis & Related Skin Types

Requests to reprint information
contained in Ichthyosis Focus
should be directed to the editor.

**The Foundation for Ichthyosis
& Related Skin Types**
650 N. Cannon Avenue
Suite 17
Lansdale, PA 19446

215.631.1411
800.545.3286

215.631.1413 fax

email — info@scalyskin.org
www.scalyskin.org

Executive Director
Jean Pickford

Editor
Maureen Tierney

Medical Editor
Amy Paller, M.D.

Editorial Assistants
Louis Giuliana
Tiffany Karst

The Foundation for Ichthyosis &
Related Skin Types is a 501 (c) 3 char-
itable organization supported by public
and private donations. All contribu-
tions to the Foundation are tax
deductible to the full extent of the law.

The editor invites your correspon-
dence. We welcome your comments,
observations and suggestions. Please
send your letters to Ichthyosis Focus
at the address listed above.

Ichthyosis Focus is provided as a
service to members of the
Foundation as a medium for the free
exchange of information. Neither the
Foundation for Ichthyosis & Related
Skin Types, its Board of Directors,
its Medical Advisory Board, nor the
Focus Editors endorse any treatments
or products in Ichthyosis Focus.
Views and opinions expressed in this
publication do not necessarily reflect
the views of the Foundation or
Foundation officials.

Correspondence Corner

Dear Members:

I am Danny Vaughn, from Roberta, Georgia. I am interested in speaking to others in my area who have ichthyosis, particularly CIE. If you are interested in corresponding with me, you can reach me at:

P.O. Box 748
Roberta, GA 31078
478-825-1340

I am looking forward to hearing from you.

Danny Vaughn
Roberta, GA

Dear Jean, and Ladies and Gentleman of F.I.R.S.T.:

I am 46 years old and have Ichthyosis Vulgaris. For many years I had no clue as to how to deal with this situation. I tried all the creams, ointments, and lotions to no avail. I thought I was destined to a life of severely dry skin, discomfort and embarrassment. Then quite a few years ago, I discovered a product that completely changed my life. The product was *Clairol Herbal Essence Shampoo for Normal Hair for Balanced Cleaning and Conditioning* (that is exactly how the label reads from top to bottom). I have no idea why, but this product eliminated all the flaking and scaling from my scalp, forehead, nose, ears, cheeks, neck, chest, arms, and legs, virtually my entire body! I don't know if when I rinsed my hair in the shower it rinsed over the rest of my body, but with continued use I was a free man. NO DRYNESS, PERIOD!!! As long as I used that product, my skin (and my life) was as normal as someone that did not have ichthyosis. Then one day I went to re-stock my supply of this product and found out that it was discontinued. (I used to buy 20-30 bottles at a time). Sure enough, after I completely ran out of the product, my skin problems returned as mean and as nasty as ever! I thought to myself if one shampoo and conditioner worked for me than surely there must be another one out there that would work also.

After months of trying different products, I found one that worked almost as well (*White Rain Plus Revitalizing Formula Shampoo and Conditioner*). But that too was discontinued after several years. Another search led me to another 2-in-1 shampoo and conditioner (*Loreal Vita Vive Daily Care for Normal Hair 2-in1 Multi-Vitamin Shampoo & Conditioner*) that worked almost as well as the original, but it also has been discontinued. And I have yet to find another product that works as well.

I have tried calling and writing all the companies that made these products but they do not seem interested in helping. I have no idea why these three products worked out of all the ones I tried, but I do know this: There is an ingredient or combination of ingredients in these 2-in-1 shampoo conditioners that stop this disease and its dryness in its tracks! With any one of these products my life was normal and happy and my ichthyosis was not a problem. Without these products my life is a nightmare. I know these products helped me, and I have to believe there is something in them that will help others with similar problems. I beg of you to please help me, and others like me. Thank you very much for taking the time to read this long letter. I will do anything I can to help you help us.

Sincerely dedicated to help,

Tom McClune
Salamanca, NY

Foundation Resources

Resource Fact Sheets

A new fact sheet on the topic of "Itching" has been added to the Foundation's resource fact sheet series. The resource fact sheets are designed to offer helpful hints about issues related to ichthyosis. "Itching" offers very comprehensive information on the troublesome issue of the itch associated with several forms of ichthyosis. Other topics available are:

- Ear Wax and Scale
- Overheating
- Retinoids
- Scalp Scale

The resource fact sheets are available to all Foundation members. Simply go to our website, www.scalyskin.org, to order your complimentary copy. Please provide your name, address, phone number, and name of the resource sheet you are requesting. The office staff will send it immediately. Or

call Maureen in the national office, 1-800-545-3286, or use info@scalyskin.org, and provide the same information. Other topics will be added to the resource fact sheet series. Please let us know if you have a suggestion for a topic.

International Support

The Ichthyosis Support Network regularly hears from individuals overseas who are looking for support in their local areas. Several countries do host ichthyosis support groups, although most do not. In order to better serve our international members, the Ichthyosis Support Network will develop *Support Contact Lists* in countries where we have a significant membership but there is no formal local organization for the ichthyoses.

We are starting with our friends in Australia and New Zealand, by compiling

a list of our members to share with other members and anyone who may contact the Foundation from those countries in the future. Members who submit their name to this list will be giving permission for their contact information to be shared with others. Members can choose how much personal information they wish to share; however, address, phone number, or email address are required.

If you live in Australia or New Zealand and would like to be a resource for someone else with ichthyosis in your area of the world, please contact Maureen in the foundation office, 650 N. Cannon Ave., Suite 17, Lansdale, PA, 19446, 1-800-545-3286, or at info@scalyskin.org.

A current list of the international ichthyosis groups is available from the foundation office. *

Senior's Speaking

Seniors Speaking is a new column devoted to the needs and experiences of our members who are 55 and older. Please direct comments, suggestions or contributions to this column to the Foundation office by calling 1-800-545-3286, or email us at info@scalyskin.org.

Dear Readers:

I have finally found relief from my severe itching with a product prescribed by my doctor. Triamcinolone Acetonide Cream (USP - 0.1%), manufactured by Alpharma, contains a high level of hydrocortisone. I have ichthyosis vulgaris, and this product offers me the most relief I have ever had for this problem.

George Powell
Mobile, AL

Medical Editor's Note: Some individuals with ichthyosis vulgaris also experience atopic dermatitis. Red, itchy patches of skin characterize dermatitis. For more information on the itching associated with ichthyosis, request the Foundation's resource fact sheet on Itching.

Dear Friends:

I am a 68 year-old grandfather. I have lived all my life with ichthyosis. It was not until my grandson was three years old (he has the condition) and his pediatrician told my daughter to try

continued on page 15

New Emollient for F.I.R.S.T. Members (30% Urea + 10% lactic Acid)

MONEY BACK GUARANTEE

Hundreds of F.I.R.S.T. members find our odor free, non-greasy 10% urea + 10% lactic acid lotion improves skin & scalp better than prescription products.

\$15.99 for a 16-oz bottle

Now try our more potent 30% urea + 10% lactic acid lotion

\$12.99 for a 4-oz bottle



To order: (800) 668-8000 • www.dermaltherapy.com

Recent Advances in Molecular Genetics of Ichthyosis

continued from page 1

a German ancestor (founder effect). It leads to the making of incorrect, nonfunctional transglutaminase-1. The enzyme is essential for forming the horny layers of the skin. Transglutaminase-1 normally functions as super glue that cross-links numerous structural proteins in the epidermis facilitating the collapse of cells to cornified remnants. However, it is also necessary for attaching epidermis-specific fats (lipids) to this protein envelope. The diminished or absent transglutaminase-1 activity in patients with LI seriously disturbs the complex process of cornification and results in scaling. Comparisons of patients with and without detectable *TGM1* mutations revealed that *TGM1* defects are most commonly associated with 'classical' LI, although some patients with mild to moderate redness or white, gray and smaller scales carry *TGM1* defects. The etiology of LI in patients without *TGM1* mutations remains elusive. Two other genes have been mapped to chromosomes 2q33-q35 and 19p12-q12, respectively, but their identity and functions of the corresponding proteins are still unknown.

The clinical features of LI widely overlap with non-bullous Congenital Ichthyosiform Erythroderma (CIE), another autosomal recessive ichthyosis. Most affected individuals are born with a collodion membrane, which subsequently evolves into generalized scaling and redness of the skin. In contrast to 'classic' LI, scales are usually white, fine and powdery, although they may become larger and darker on the lower legs. Extensive thickening of the skin of the palms and soles is also a common feature of CIE. In the vast majority of families, CIE is inherited as an autosomal recessive trait, although autosomal dominant inheritance has been occasionally observed. Similar to LI, CIE can have several different causes. A small group of patients, especially those with less intense redness of the skin, carry inactivating mutations in *TGM1* as discussed above. Other patients originating from the Mediterranean basin were found to harbor mutations in one of two functionally related genes, *ALOXE3* and *ALOX12B*, both located on the short arm of chromosome 17. These genes produce 2 enzymes belonging to the lipoxigenase family that are involved in the metabolism of skin fats (lipids), such as polyunsaturated fatty acids, phospholipids and triglycerides. The reported mutations result in loss or inactivation of the enzymes. Although the

specific functions of each enzyme are still unknown, they are assumed to operate jointly in a common metabolic pathway crucial for maintaining the lipid barrier of the epidermis. In the future it will be necessary to determine if *ALOXE3* and *ALOX12B* mutations play a role in CIE patients of other geographic and ethnic backgrounds or if other genes might be involved. Until then, the underlying genetic basis of CIE in most patients awaits identification.

Sjögren-Larsson Syndrome (SLS) is an autosomal recessive disorder characterized by congenital ichthyosis, spasticity, and mental retardation. At birth, the skin may show varying degrees of redness and scaling with accentuated skin markings. While the redness subsides over time, thickening and scaling of the skin tend to worsen, especially on the abdomen, in large skin folds and on palms and soles. In contrast to many other ichthyoses, the skin is very itchy. During early childhood neurological problems, such as stiffness of arms and/or legs and difficulties with walking, develop. Another characteristic sign are glistening white dots in the back of the eyes. The involvement of the central nervous system slowly progresses and results in developmental delay, speech defects, severe mental retardation and a host of other problems. SLS is caused by deleterious mutations in the gene *FALDH* on the short arm of chromosome 17. The gene produces another enzyme involved in lipid metabolism, Fatty Aldehyde Dehydrogenase. This enzyme is part of a pathway that produces fatty acids, which are important for the making of epidermal lipids as well as the degradation of certain phospholipids in the brain. The majority of the more than 50 different mutations detected in the SLS gene are unique to each family. Nevertheless, research revealed a few mutations that are common among individuals of Northern European and Middle Eastern origin. This knowledge can be very helpful for a fast molecular diagnosis based on DNA tests. Other specific and reliable diagnostic tests are the measurement of enzyme activity and the detection of elevated free fatty alcohols in cultured skin cells (fibroblasts) or the blood.

A final example is Comèl-Netherton Syndrome (NTS). This autosomal recessive ichthyosis is associated with hair abnormalities (bamboo hair, alopecia) as well as abnormalities of the immune system, including

elevated levels of immunoglobulin E in the blood, susceptibility to skin and respiratory tract infections and allergic reactions. A recent study revealed that almost 1 in 5 of all babies born with generalized red and scaly skin have NTS. In the newborn period, affected children may suffer from fluid and electrolyte imbalances, failure to gain weight and thrive, and life-threatening infections. Later, the skin disorder in NTS either remains generalized closely resembling CIE, or change into scaling, itchy plaques with prominent borders. The latter variant is named 'ichthyosis linearis circumflexa'. Despite these clinical differences, both variants are caused by recessive mutations in the gene *SPINK5* on the long arm of chromosome 5. This relatively large gene contains the genetic blue print for producing an inhibitor of protein-degrading enzymes named LEKTI (Lympho-Epithelial Kazal-Type Inhibitor). Over 50 mutations of different types and location have been detected so far, 65 percent of which result in the complete loss of LEKTI enzyme due to disrupted transcription from DNA into protein, while the remainder are thought to compromise enzyme function. A few mutations seem to be more common among Turkish or Arab populations, but similar to LI, most families carry unique mutations. The LEKTI enzyme is expressed in the skin, mucous membranes, tonsils and thymus, and when needed, can be quickly cleaved into 15 active domains that suppress enzymes like trypsin. The specific biological targets of LEKTI in human tissues, however, are currently unknown. In principal, loss of LEKTI will lead to uncontrolled and prolonged activity of destructive, protein-degrading enzymes. In the skin, this process disturbs the delicate balance between lipid-processing enzymes and hastens disintegration and shedding of the horny cells, thus severely disrupting the barrier function. In addition, the skin and mucous membranes lose protection against invading microorganisms and inflammation, which further contributes to the disease.

As illustrated with these five examples, molecular genetic research of the ichthyoses has been incredibly successful in unveiling the underlying defects of numerous single gene disorders, although the list of disease genes is far from complete. Often the question is asked: 'What can modern genetics do for us?' The previous sections aimed to demon-

continued on page 6

In general, the goal in taking care of ichthyosis is to hydrate (moisturize) the skin, hold in the moisture, and keep scale thickness to a minimum.

**Foundation for Ichthyosis & Related Skin Types, <http://www.scalyskin.org>*



Aquaphor® Healing Ointment helps heal dry skin associated with ichthyosis. Its unique petrolatum-based formulation combines a moist environment with the benefits of a semi-occlusive barrier that allows skin to breathe and absorb fluids.

Aquaphor is ideal for daily use because it is hypoallergenic, non-comedogenic, fragrance and preservative-free. Aquaphor Healing Ointment is safe enough for even the most sensitive skin.

Special Offer
For Readers of this F.I.R.S.T. Newsletter

MANUFACTURER'S COUPON EXPIRES 06/30/03

Save \$2.00
 on any
 Aquaphor®
 Product

(NO TRIAL SIZES)



Consumer: Coupon good on the purchase of any Aquaphor® Product, no trial sizes. Limit one coupon per item purchased. Any other use constitutes fraud. Not good with any other special offer. Consumer must pay sales tax.

Retailer: You are authorized to act as our agent to redeem this coupon and we shall reimburse you at face value plus 8¢ handling in accordance with our redemption policy. Cash value 1/100¢. Copies available upon request. Offer void if copied and where prohibited, taxed or otherwise restricted. Mail to: Beiersdorf Inc, PO Box 880504, El Paso, TX 88588-0504. Good only in USA.



Recent Advances in Molecular Genetics of Ichthyosis

continued from page 4

strate how gene discovery and molecular biological research have advanced our insight into the different mechanisms leading to disturbed cornification and skin barrier function. It is now possible to categorize ichthyoses not only based on their clinical symptoms but also based on the underlying genetic defects. This new information also provides an invaluable basis, from which the biological consequences of mutations and the pathways of disease can be explored in detail, such as the lipid metabolism of the skin. Knowledge of the genes and mechanisms of disease will be crucial for conquering the next great challenge of developing new therapeutic approaches specifically tailored to these disorders. Animal models of human ichthyoses are being developed, such as mice deficient for transglutaminase-1, which exhibit a skin disorder similar to LI with impaired barrier function leading to water loss and abnormal absorption through the skin. Such models allow the systematic evaluation of the functions of specific epidermal proteins as well as testing of new therapeutic modalities. In parallel, several approaches are being explored to replace the lost enzyme activity of transglutaminase-1 or LEKTI in the epidermis or to deliver normal gene copies directly to the skin. While much more work, time and money will be needed to develop practicable and effective new treatments, molecular genetics has paved the way for these developments.

One of the immediate benefits of genetic research, however, is the development of molecular tests to confirm a clinical diagnosis, allow prenatal or presymptomatic testing, determine the risk of disease for members of families and improve genetic counseling. Establishing or ruling out a clinical diagnosis can be especially helpful in those types of ichthyoses, in which scaling of the skin occurs before the onset of other organ manifestations, as in neutral lipid storage disease or SLS. In other disorders, such as Netherton syndrome, severe health problems may develop soon after birth and during infancy, while diagnostic clinical features or laboratory results will not be available until later. Thus molecular testing can help to recognize the correct diagnosis and to make predictions about the course and progression of disease. Nevertheless, since

since the treatment of most ichthyoses is still limited to easing symptoms, the outcome of molecular testing often has little immediate impact on the treatment of patients treatment of patients with an inherited ichthyosis.

Knowing exactly which DNA mutations cause the disorder in a patient or family also offers the possibility of testing a baby before it is born (prenatal testing) or determining the carrier status of family members. Reliable and early prenatal molecular testing has been well established for some disorders with severe and sometimes fatal outcomes, such as NTS and SLS, and can be performed using chorionic villus sampling as well as amniocentesis. In LI and CIE, DNA-based testing can replace difficult and invasive fetal skin biopsies, but currently remains limited to detecting disease-causing mutations in *TGM1*.

Biological material for molecular testing can be relatively easy to obtain. Most tests are performed from DNA, which is extracted from a small venous blood sample or buccal swabs. For screening of large genes, such as *TGM1*, or if DNA mutations alter the size of the DNA transcript, it might be necessary to extract messenger RNA from a small skin biopsy. In addition, certain biochemical assays (for example in SLS) or the detection of a protein deficiency in the skin (for example, loss of transglutaminase-1 in LI) requires a skin biopsy.

Most ichthyoses are caused by distinct DNA mutations that are specific to the affected individual or family. Finding these changes is often costly and labor intensive. Therefore, these specialized tests are only performed in very few research and commercial laboratories worldwide. Multiple different methods and strategies have been developed to identify DNA mutations, each of which has its advantages and limitations. Direct sequencing of the DNA sequence of a gene is the most sensitive but often also the most costly approach. Depending on the nature and location of mutations, it is possible to identify up to 95% of all disease-causing mutations. Faster and less expensive methods, such as heteroduplex analysis, are often used to screen large genes for unknown mutations. The gene is divided into multiple overlapping frag-

ments, which are a million times multiplied by a method called polymerase chain reaction (PCR), and analyzed for differences in the DNA sequence. Once aDNA change is suspected in such a gene fragment, the exact mutation will be determined by DNA sequencing.

Despite the great advances in technology and molecular testing, the widespread application of diagnostic testing is curbed by a number of limitations. For some disorders, tests might not be currently available. Many disorders, including LI and CIE, are caused by mutations in more than one gene and not all of these genes have yet been identified. Before testing, there are no clinical or biochemical signs that would allow predicting if a patient carries mutations in *TGM1* or in another gene. Another problem already mentioned is the fact that no assay is sensitive enough to detect all mutations. Depending on the nature of the tests performed, approximately 5% to 20% of mutations might be missed, and this number might be even higher in certain disorders, such as Darier disease and Hailey-Hailey disease. For all single gene disorders there are exceptions to the rules of traditional Mendelian inheritance, which complicate or defy test interpretations. Examples are reduced gene expression leading to differences between the genotype (mutation detected) and the phenotype (no signs of disease), and genetic mosaicism, in which case some cells of the body carry a mutation while others do not. Finally, moral and ethical considerations especially for prenatal testing or testing of individuals before they show symptoms of disease (presymptomatic testing) should also be mentioned here. To evaluate availability, options and limitations of DNA-based testing, seeking genetic counseling by trained professionals in medical genetics is advisable.

In summary, striking progress has been made in our understanding of the ichthyoses on a molecular level. Molecular genetic testing has become available for a number of ichthyoses and may aid and complement the clinical diagnosis, although multiple limitations require careful consideration. Research now faces the next challenge of developing effective treatments for affected individuals. ❀

Take a New Approach

in healing chronically dry, itchy, flaky skin



-  An elegant, therapeutic emollient with the occlusive properties of an ointment and the cosmetic appeal of a cream
-  Moisturizes while repairing and protecting your skin barrier from potential irritants
-  Hypoallergenic, fragrance free, irritant free, non-comedogenic

Available in the following convenient sizes:

30g tube (NDC 0496-0819-30)

100g tube (NDC 0496-0819-01)



ASK YOUR PHARMACIST FOR SBR-LIPOCREAM[®]

\$2 Rebate on your next purchase of

SBR-Lipocream[®]

Skin Barrier Repair Cream


Name _____

Address _____

City _____ State _____ Zip _____

Please check the size you purchased

30g _____ 100g _____



Mail this completed form, receipt of your purchase of SBR-Lipocream along with the UPC label to:
Ferndale Laboratories, Inc. ATTN: SBR-Lipocream Rebate, 780 W. 8 Mile Rd., Ferndale, MI 48220

Annual Report *Fiscal Year 2002*

Executive Director's Report

Dear Members and Friends:

The Foundation for Ichthyosis & Related Skin Types is twenty-two years old and stronger than ever! I am inspired by our progress as we enter our third decade of helping the ichthyosis community. Due to generous contributions from our members and corporate partners, we continue to maintain strong financial stability. As always, our mission is dedicated to providing support, information, education, and advocacy for affected individuals and their families, and supporting research into causes, treatment, and cures for the ichthyoses. During these challenging fiscal times, I am very proud to present the Foundation's Annual Report for the fiscal year ending September 30, 2002.

Jean



Board of Directors



Laura J. Phillips
President
Affected, Lamellar Ichthyosis
Senior Manager,
Ernst & Young LLP
Cleveland, Ohio



Philip Fleckman, MD
Professor, Division of Dermatology,
University of Washington
Principal Investigator, The
Registry for Ichthyosis & Related
Disorders
Seattle, Washington



Daniel J. Siegel, Esq.
Legal Counsel
Father of Sons, X-linked Ichthyosis
Attorney, Anapol, Schwartz, Weiss,
Cohan, Feldman & Smalley, PC
Philadelphia, Pennsylvania



Leonard M. Milstone, MD
Vice President
Professor of Dermatology
Yale University School of Medicine
New Haven, Connecticut



Gloria Graham, MD
Associate Professor, Dermatology
Wake Forest University Baptist
Medical College
Winston-Salem, North Carolina



Rita Tanis
Founding Member
Affected, Lamellar Ichthyosis
Real Estate Agent
Fairfield County, Connecticut



Elizabeth A. Gray
Chief Financial Officer
Mother of Affected Son,
Lamellar Ichthyosis
Adjunct Professor,
Bellevue University
Bellevue, Nebraska



Elena Levitan
Past Executive Director
Haverford, Pennsylvania



Peyton Weary, MD
Father of Children, EHK
Former President of American
Academy of Dermatology
Professor of Dermatology,
University of Virginia
Charlottesville, Virginia



Tiffany Karst
Secretary
Mother of Affected Daughter,
Lamellar Ichthyosis
Medical Social Worker,
University of Kansas Hospital
Kansas City, KS



Amy Paller, MD
Division Head, Dermatology
Professor of Pediatrics and
Dermatology, Feinberg School of
Medicine
Northwestern University
Chicago, Illinois



Mary Williams, MD
Founding Member
Adjunct Professor of Dermatology &
Pediatrics
Chief of Pediatric Dermatology
Service, University of California
San Francisco, California



Michael Dunleavy
Past President
Uncle of Affected Children, CIE
Corporate Vice President,
Crown Cork & Seal Company
Philadelphia, Pennsylvania



Donna Rice
Immediate Past President
Mother of Affected Daughter,
Unknown Type
Katy, TX



Peter Woodford
Affected, Ichthyosis Vulgaris
Departmental Manager 15
State of Michigan, Department of
Management & Budget
Northville, Michigan

Annual Report *Fiscal Year 2002*

Chief Financial Officer's Report

Dear Members and Friends:

Fiscal Year 2002 began October 1, 2001, just weeks after the terrible and unforgettable events of September 11. These events had a direct effect on our finances, as they did for many non-profit organizations. Contributions were down significantly from fiscal year 2001. The current economic climate has had a slight negative effect on the Foundation. The primary objective of the Foundation's conservative investment policy is to preserve and protect its assets. However, during fiscal year 2002, the Foundation's net assets decreased slightly, from \$271,000 to \$266,000. These losses are minimal when considered in light of the overall economic environment.



In spite of these difficulties, fiscal year 2002 included many accomplishments. In March 2002, the Foundation's board of directors approved a five-year strategic plan that focuses the Foundation's efforts on the issues that you, our members, have told us are important, such as research funding, programs, and services. Thanks to referrals from current members, dermatologists, and the Foundation's website, membership increased by 34% during 2002. Our physician referral list also increased, by over 300%. The Ichthyosis Support Network, funded by Beiersdorf, now includes 163 volunteer peer counselors. Over 225 members attended the bi-annual family conference in Seattle, Washington, last July. Seven families received direct financial assistance through the Jane Bukaty Membership Fund. The Foundation continues to be an important source of support for families affected by ichthyosis, by providing information, advocating for rare disease legislation, and supporting research into the causes and cures of ichthyosis.

The Foundation is fortunate to have a highly dedicated and hard-working staff making the most of your donations and identifying alternate sources of funding. For example, in January, we introduced new Honor and Memorial cards that allow members to recognize important events in the lives of their family and friends through a donation to the Foundation. In May, a new educational brochure was introduced, thanks to the generosity of Felton Design and Clare Printing. In July, members from all over the world traveled to Seattle, Washington, to learn, meet other families who have been affected by ichthyosis, and have fun. With the support of more than twenty corporate sponsors and donors, costs for the conference were kept low while the number and quality of sessions was at an all-time high.

I appreciate the opportunity to serve all of you and hope that you are as proud of the Foundation's achievements as I am. I also hope that you will continue to be generous in your support of the valuable work the Foundation does. In 2003, we are embarking on a major fundraising campaign to increase the monies available for ichthyosis-related research, a major issue identified during the strategic planning process. Any donations, large or small, will help us to achieve our ultimate goal of finding a cure.

Sincerely,
Elizabeth A. Gray
CFO, Board of Directors.

* This Statement of Financial Position is excerpted from the Foundation's audited financial statements as of September 30, 2002. A complete copy of the audited financial statements and the independent auditors' report are available and can be obtained by calling the national office at 215-631-1411, or 1-800-545-3286

	2002		2001	
ASSETS				
Current assets:				
Cash	\$ 46,019	\$ 11,000		
Marketable securities	117,273	117,096		
Current portion of long-term investments	39,490	31,500		
Other receivables	2,817	988		
Prepaid expenses	377	3,882		
Total current assets	206,076	284,466		
Cost, previously reported	39,004	49,000		
Prepaid receivables, net of current portion	16,211	13,899		
Prepaid and equipment, net	5,992	12,893		
	\$ 271,283	\$ 274,258		
LIABILITIES AND NET ASSETS				
Current liabilities:				
Accounts payable and accrued expenses	\$ 4,377	\$ 3,271		
Accrued payroll and benefits	4,070	3,997		
Deferred revenue	1,000			
Total current liabilities	9,447	7,268		
Net assets:				
Unrestricted	191,829	197,198		
Temporarily restricted	62,294	64,891		
Previously reported	15,960	10,169		
	270,083	272,258		
	\$ 271,283	\$ 274,258		

2002 Contributor's List

\$100 - \$249

Nancy Abrams
Harvey Adams
Anita Adams
David Adorno
Tom & Jennifer Alba
George & Marilyn Allison
Joan Alnor
American Academy of Dermatology
Carl & Shirley Anderson
Marjorie Andrews
Merritt Andrews
David & Cindy Ashton
Lisa Bachand
Baker Brothers Advisors
Annette & Harry Barbash
Margaret Batson
John Bellucci
Ann Benedetto
Denise & Marc Benedetto
Angelo Benedetto
Reba Benson
Dianna Berg
Jim & Donna Bernstiel
Elwood Bernstiel
Paula Bevilacqua, MD
Robert Bialer
Gary Bierwagen
Julie Billings, MD
Elizabeth Blackford
W.B. & Jane Blackford
Patricia Blackwell
Teresa Blanton
Karen Block
Margaret Boas
Meshell Boydston
Nancy Brooks
Randy Brown
Gerald Bruey
Patrick Burkhardt, MD
Mary Jane Burt
John Burton
Richard Butler
John & Debra Butler
Lee Caldwell
Rebecca Cecconi
Peter Cerilli
Sarah L. Chamlin, MD
Christine Chan
Leslie Chapin
Keith Charsha
Joseph & Julianne Ciolino
Classic Designs & Printing
Diana Clifton
Pamela Cohan
John Compton, PhD
Brian & Joyce Conneely
John & Jean Cox
J. O. Cunningham
Irene Davidson
Amie Jo DeGarmo
Harmeet Dosanjh
Kristin Driggs
LouAnna Dugan
Julie Dunipace
Dennis & Schuyler Eastin
Elizabeth Egan
Charles Eichhorn
Barbara & Steve Elfers
Renee Howard Erle
James Ertle
Nancy Esterly, MD
John & Diane Farley
Linette Finstad
Mary Fitzpatrick
Five Star Quality Care, Inc.
Ada Foster
Jeannette Foxe
Michael Franzblau, MD
Tomi & Duane Friddle
Sam Fulk, MD
Beth Gaddy
James & Kathleen Gaffney
Joseph Galluccio
Maria Garzon, MD
William Geismann
John Geisse, MD
Linda George
Diana Gilbert
Macaria Gorena
Susan Granados
Helen Griffin
Gunwant Guron
Martin Haas
Doug & Barbara Hallett
Geoffrey Hamill, RN
Terri Hamrick-Oeschger
Jon Hanifin, MD
William & Linda Hatfield
Kristi Hawk
Susan Heaton
Donna Heilweil
Eleanor Hertzog
Sandy Heyburn
Frances Hiner
David & Pamela Hines
Jody Hollenbeck
Alice & Michael Hricak
Paul & Janice Hudson
Harold Hudson, MD
Ted Isaacman
Tim Jack
Dawn & Joe Johnson
Marie-Louise Johnson, MD
Robert & Patricia Jones
Lori Jones
Anthony Jordan
Tiffany Karst
Stuart M. Katz
Mike Kell
Paul Kelley
Vern Kelley
Ho Jin Kim, MD
Jack King
Samuel Kirby, MD
Harry Kirschner
Lucy Kjellerson
Kelly & Mark Klafter
Carol Klafter
Edward Klopp
Cynthia & John Kohl, III
Gerald Krueger
Wilmer & Virginia LaBrant
Toni Langsfeld
James Lapides
Aileen Leahey
Cynthia & Lance Leshner
Robert Levit
Gregory & Carol Licalzi
Gaetano & Mary Licursi
Steven & Janna Lloyd
Sandra Lozier
The Lucas Family
Howard Maibach, MD
Nancy Mantel
Jennie Maresca
Brian Marshall
Guy Mason
Charles Maxey
Dennis & Marsha McAlister
Lauren B. McLamore
Dennis McMillan
Nicole McMillian
Jennifer McNiff
In Memory of Bill Robertson
In Memory of Charles (C.H.) Kindred
Diane Mencia
Judy Messer
Laurence Miller, MD
Greater Pittsburgh Masonic Center, Milnor
Lodge No. 287
Vivian Milstone
Patricia Mondri
Kathleen Moran
Patti Napoli
Patricia Oliver
Herdis Olson
Seth Orlow, MD, PhD
Pascagoula Elks Auxiliary
Don & Leslie Patterson
Mary Ann Pedtke
Eustolia Perez
Jean Peters
Theresa Phaneuf
Laura & Chris Phillips
Michael Pinnisi
Mary Alice Ponso
Emily Preston
Joseph Proscia
Susan Purcell

2002 Contributor's List

Christopher Raschke
Micaela Rauch
Lisa Regina
Catherine & Jack Rice
Marcia Richmond
Richard Rival
Janice Roberts
Barbara Robertson
Kathryn Rogers
Linda Rogers
Phillip Rosenberg
Sarah Rosenberg-Geilen
Richard Rossman
Safeway
Juliani Salim
Stephanie Sawyer-Ames
David & Linda Schell
Ramona Schiller
John Schira
Paul Schneiderman, MD
Laverne Schwartz
Eric Schweighoffer
The Scirica Family
Lisa & Christopher Short
Elliot & Phyllis Shulman
Nanette Silverberg
Michael Sisack, MD
John & Leanne Skokan
Easton B. Smith
Mark Smith
Jeanne Marie Smith
Edward Smith
Starlee Speers
Pam Sproull
Ellen & Patrick Spurling
Melissa St. Amant
Marian Stanton
Larry & Brenda Staton
Peter Steinert, PhD
Cynthia Stone
Bonnie Straka, MD
Elise Sturgeon
Susan Suda
Leilani Sundt
Carol Swanson
Robert Tapley
Michael Taylor, MD
TechNiche Intl.
Maria Tessinari
Jennifer Thoelke
Roger & Tina Thomas
Norma Treat
Janice & Sam Unruh, Jr.
Judy Van der Wielen
Martha Van Zile
Barry Waldman, MD
Sharon Waters
Mark Weber
Clayton Wheeler
Walter & Linda Wiewell, III

Barbara Williams
Mary Williams, MD
Michael Workman
Andrew Yaffee
Eric Zugerman

\$250 - \$499

Mohinder & Jasjot Anand
Les Avakian
Karoline Freed Biggs
Robert & Debra Bowie
Richard & April Cobb
Jessie Deely
Dermal Therapy Research Inc.
Edison International
Lori Florian
Foundation for Cutaneous Research
Linda Gleed
Jacqueline Griess
Susan Haberman
Susan & Kurt Hoffman
Lanny Hoover
Brian Jones
Helen Kozinski
Arthur Lavery
Thomas & Rita Medley
In Memory of Mark Levitan
In Memory of Suzanna M. Leonovicz
Barbara Myers
Michael Potack
Tracie Pretak
David & Anna Purcell
Richardson, Askew & Burkholder
Dermatology, P.L.C.
Ben & Michelle Romero
Rosemary Ryan
Liza Santamina
Dan Siegel
Sirius Laboratories, Inc.
Patti Steinitz
Madonna Taylor
Theresa Tremmel-Anderson
Paula Wetterlund
Sammy D. Williams

\$500 - \$999

Allerderm Laboratories, Inc.
Darlene Blackwell
Frances Blankis
Isabell Blanton
Ernest Paper Products
Floyd & Agnes Evans
Beth & Steve Gray
Dona Hoar
Joe & Chris LaBarbera
Peter & Maria Lappin
Elena & Ken Levitan
Mae Malatesta
John & Agenia McCarthy

Thomas McClune
Donna Melle
In Memory of Russell Dunipace
Marcia & Tim Ohlwiler
Karen Price
Mary Raitt
Virginia Scully
SFBC/Charlotte
Ben Waldshan
Pam Yahnke

\$1000 - \$4999

American Skin Association, Inc.
BP Amoco
Henry Bukaty
Glenn D. Burton Jr.
Clay Park Labs, Inc.
Dunleavy & Associates
Francis & Albina H. Dunleavy
Ferndale Laboratories
Carol & Tom Frost
Galderma
Gateway Women's Club
Gloria Graham, MD
Herman & Joyce Karst
Merz Incorporated
National Semiconductor
Paddock Laboratories, Inc.
James & Elza Phillips
Donna & Victor Rice
Roche Laboratories, Inc.
Janet Showers-Patterson
Stiefel Foundation
Summers Laboratories
Upsher Smith
Verizon
Margaret Vernet
Carolyn Warbritton
Ruey J. Yu, PhD, OMD

\$5000 - \$9999

The Gaffney Foundation
GlaxoSmithKline
Nicholas Perricone, MD
Eugene Van Scott, MD

\$10,000 +

Beiersdorf
NeoStrata
Janet & Peyton Weary

Annual Membership Renewal

For the past several years, our Membership Renewal Campaign has been sent to you in a separate mailing. This year's renewal request is being sent to you in a different way. To make better use of our resources, I have included the 2003 renewal request in this newsletter. You are receiving this newsletter because our records currently include *you as a member*. What better way to remind you of your responsibility to renew your membership than through one of our most valuable services?

Please take a moment to make sure you are taking full advantage of the many benefits of membership:

- ***Ichthyosis Focus**, our quarterly newsletter that provides the most current information on treatments, research, and advice.*
- *Access to physicians who specialize in the treatment of ichthyosis.*
- *Participation in the Ichthyosis Support Network (ISN), connecting individuals and families with other affected members.*
- *Invitations to participate on the ISN Exchange, an email list serve for members of the ISN.*
- *Invitations to regional meetings and national conferences. Our next national conference is scheduled for July 1 - 4, 2004 in Kansas City, MO.*
- *Samples of skin care products from pharmaceutical companies.*
- *A comprehensive listing of more than 50 products that may aid in your skin care.*
- *Discounts on several skin care products.*
- *Access to the "Members Only" section of our website, www.scalyskin.org.*
- *The comfort of knowing you belong to a special group of committed people who are devoted to helping individuals and families affected by ichthyosis.*

Babies are born every day with some form of ichthyosis. Having a place to turn for advice, support, and reliable information is invaluable and can make all the difference in the world. Words cannot describe how grateful people are to learn that our Foundation exists to help them through their life's journey with ichthyosis. It is the support of our membership that enables these important services to continue.

Renew your membership today! Simply complete the envelope (inserted between the pages of this newsletter) and send your donation to the office. Our membership brings strength, hope, and force to the Foundation. I am proud to represent such a wonderful, caring group of people.

Sincerely,



Jean R. Pickford
Executive Director



Ichthyosis Vulgaris Survey

Dear Friends:

The following survey is designed to help our medical advisors understand the issues that are common to our members with ichthyosis vulgaris. As we have noted before, some of our members with vulgaris report that they experience overheating. However, the medical community does not recognize overheating as a hallmark of the disease. If you have ichthyosis vulgaris, please fill out the following survey and return it to the Foundation. We want to hear from you even if you have not experienced overheating as a symptom of your disease. You may return the survey along with your membership renewal in the envelope provided, or send it to the Foundation for Ichthyosis, 650 N. Cannon Avenue, Suite 17, Lansdale, PA, 19446, Attention: Survey.

Name _____

Address _____

Phone Number _____ Email address _____

Date of Birth _____ Country of Birth _____

Diagnosis Ichthyosis Vulgaris Other Unknown

Year diagnosed? _____ How old were you at the time? _____ Age when your skin symptoms first appeared? _____

Name and address of the doctor who gave you your diagnosis:

How was your diagnosis made? What tests did your doctor do? Skin biopsy? Electron microscopy?

Do you have a written report from your doctor confirming the test results and your diagnosis? Yes No

Do you experience overheating with your ichthyosis vulgaris? Yes No

What month of the year are you most likely to experience overheating? _____

What hour of the day are you most likely to experience overheating? _____

What activities are most likely to cause you to overheat? (Please list all that may apply: walking, gardening, sports, indoor chores, outdoor chores, etc.) _____

What physical symptoms do you experience when you are overheating?

- | | | | |
|--|---|--|--|
| <input type="checkbox"/> Feeling warm | <input type="checkbox"/> Muscle cramps | <input type="checkbox"/> Thirst | <input type="checkbox"/> Nausea or vomiting |
| <input type="checkbox"/> Increased sweating | <input type="checkbox"/> Difficulty concentrating | <input type="checkbox"/> Feeling tired | <input type="checkbox"/> Skin rash |
| <input type="checkbox"/> Shortness of breath | <input type="checkbox"/> Passing out | <input type="checkbox"/> Dizziness | <input type="checkbox"/> Not sweating at all |
| <input type="checkbox"/> Other: _____ | | | |

Ichthyosis Vulgaris Survey

Have you ever been taken to the emergency room or hospitalized for heat exhaustion or heat stroke? Yes No

If yes, what year did this happen and for how long were you in the emergency room or hospital? _____

Please describe how your skin looked when your disease first appeared. Include which areas of your body were affected (e.g. scalp, legs, chest, etc.) and if any parts of your body appeared to have thicker than normal skin.

What does your disease look like now? _____

What areas of your body are currently affected by your disease?

- | | | | | |
|---------------------------------------|---|---|--|---|
| <input type="checkbox"/> Scalp | <input type="checkbox"/> Chest | <input type="checkbox"/> Arms | <input type="checkbox"/> Lines on palms of hands increased (hyperlinear) | <input type="checkbox"/> Eczema or atopic dermatitis (red, itchy patches of skin) |
| <input type="checkbox"/> Face (front) | <input type="checkbox"/> Back (upper & shoulders) | <input type="checkbox"/> Legs | <input type="checkbox"/> Lines on soles of feet increased (hyperlinear) | |
| <input type="checkbox"/> Face (sides) | <input type="checkbox"/> Back (lower) | <input type="checkbox"/> Hands (cracked or chapped) | <input type="checkbox"/> Scales small | <input type="checkbox"/> Keratosis pilaris (red scaly bumps in the hair follicles on the sides of the arms) |
| <input type="checkbox"/> Neck | <input type="checkbox"/> Stomach | <input type="checkbox"/> Feet (cracked or chapped) | <input type="checkbox"/> Scales large | |

Has your disease improved with age? _____ Gotten worse? _____ Remained the same? _____

Do you or any members of your family have any allergies? Yes No

If so, to what? _____

Do you or any members of your family have asthma? Yes No

Do you or any members of your family have eczema? Yes No

Please list all the skin care products and medications you use in caring for your skin. Include how many times a day you use each.

Please tell us anything else you would like to share about your disease. _____

Senior's Speaking

continued from page 3

AmLactin 12% Moisturizing Cream that I found help for my skin. I tried all my life to find creams, oils, etc., that would actually help my condition. The summer heat of the North would help from July to September, then it would return. This is the only product that has helped. It does such a good job that, if I apply it twice a day, it will absolutely control this condition.

If there had been such a product when I was young, it would have saved me many embarrassing moments, such as gym class in high school. I am only sorry that I was 65 years old before it came along. It is available at Wal-Mart and other drug stores. You do not need a prescription, but it is usually kept behind the counter, so you will have to ask for it. It will take about a

week of application before you will see a change. Also, it is odorless.

**Edmund E. Smith
Hilton, NY**

Dear Friends:

I spent my childhood wearing long-sleeved white blouses, as I had no idea why I had dry, itchy, scaly skin. Occasionally, I was called "alligator skin." It wasn't until after I was married that I went to a dermatologist who put a name to my condition. He said, "You have ichthyosis. You are born with it; you will live with it; you will die with it." He gave me quite a few tips on what to do, along with a bag full of lotions and creams to experiment with. He also advised me not to go from doctor to doctor and spend

a lot of money because there was no cure. Years ago, the only lotion I had used smelled very medicinal, and it did not work that well. We are fortunate to have so many products on the market these days, and an organization, F.I.R.S.T., so we know we are not alone. Two products that I found helpful are "She Butter Shea It Isn't So" from Bath and Body Works, and their Body Cream, which comes in various fragrances.

I'd like to issue a word of warning about heat exhaustion. I have had it twice now, so I am very cautious about overheating. I have grown more susceptible as I age. Beware – the sun is not your friend.

**Carolynn Petersen
Wauwatosa, WI**

NIAMS Day 2003

Jean Pickford, Executive Director, and Maureen Tierney, Program Director, traveled to Washington, D.C., for NIAMS Day 2003 on March 10 and 11. This two-day event brings together patient advocate groups who benefit from research sponsored by the National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS) branch of the National Institutes of Health. (NIH).

Jean and Maureen met with Dr. Stephen Katz, NIAMS Director, and other members of the Coalition of Skin Diseases. Dr. Katz updated the group on the Institute's recent activities and its current focus on clinical research, and some other initiatives:

- Improving the coordination and support between other institutes for multi-symptom diseases.
- Improving the methodology of measuring patient awareness in prevention strategies, lifestyle behavior and the workplace environment in relationship to skin disease.
- Sponsorship of a meeting to analyze the burden of skin disease.

- Partnerships with several large disease groups for research studies.
- Meetings to discuss the surge of immunomodulation drugs.



- Continuation of the loan repayment program to encourage young investigators to choose research as

a career path.

- Providing training grants to young investigators, in partnership with the Herzog Foundation.
- Providing valuable resources for the dissemination of information on musculoskeletal and skin diseases.

Members of the NIAMS Coalition then broke into small groups and visited our area representatives in Congress and their Senators. Our purpose was to stress the importance of increasing the NIH budget, particularly NIAMS, in 2004. Over the past five years, Congress has successfully fulfilled its plan to double the NIH budget. Although it is not realistic to expect such generous increases in the future, it is important to keep yearly increases substantial. The funding must continue in order to capitalize on the research advances of the past few years, or we risk the loss of new and innovative theories.

We thank the American College of Rheumatology for coordinating NIAMS Day and scheduling our appointments with the Representatives' and Senators' staffers.

The First and Only Generic to Lac-Hydrin®** 12% Lotion

12%
LAClotion™
(AMMONIUM LACTATE)
LOTION



LAClotion™ 12% (ammonium lactate) Lotion

Rx only

For topical use only. Not for ophthalmic use.

Indications and Usage

LAClotion is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.

Contraindications

Known hypersensitivity to any of the label ingredients.

Precautions

General: For external use only. Avoid contact with eyes, lips or mucous membranes. Caution is advised when used on the face of fair-skinned individuals since irritation may occur. A mild, transient stinging may occur on application to abraded or inflamed areas or in individuals with sensitive skin.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Ammonium lactate was non-mutagenic in the Ames/Salmonella/Microsome Plate Assay. Reproductive studies in rats given lactic acid orally showed no effect on the sex ratio of the offspring.⁵

Pregnancy

Teratogenic Effects. Pregnancy Category C:

Animal reproduction studies have not been conducted with LAClotion. It is also not known whether LAClotion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. LAClotion should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when LAClotion is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of ammonium lactate have been demonstrated in infants and children. No unusual toxic effects were reported.

Adverse Reactions

The most frequent adverse experiences in patients with xerosis are

transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation. Due to the more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).

Overdosage

The oral administration of ammonium lactate to rats and mice showed this drug to be practically non-toxic (LD₅₀>15mL/kg).

Dosage and Administration

Shake well. Apply to the affected areas and rub in thoroughly. Use twice daily or as directed by a physician.

How Supplied

225 g (NDC 0574-2021-08) plastic bottle and 400 g (NDC 0574-2021-16) plastic bottle.

References

- Blank IH: Further observation on factors which influence the water content of the stratum corneum. *J Invest Dermatol* 21: 259-271, 1953.
- Blank IH: Factors which influence the water content of the stratum corneum. *J Invest Dermatol* 18: 433-440, 1952.
- Middleton JD: Sodium lactate as a moisturizer. *Cosmetics and Toiletries* 93: 85-86, 1978.
- VanScott EJ and Yu RJ: Modulations of keratinization with α -hydroxy acids and related compounds. In: *Recent Advances in Dermatopharmacology*, P. Frost, E.E. Gomez and N. Zaias (eds) Spectrum Publications, Inc. NY, 211-217, 1977.
- D'Amour FE: Effects of feeding sodium bicarbonate or lactic acid upon the sex ratio in rats. *Science* 79: 61-62, 1934.

Paddock Laboratories, Inc. Minneapolis, MN 55427
For complete product information, call 800-328-5113
or log on to www.laclotion.com

**Lac-Hydrin® is a registered trademark of Westwood-Squibb Pharmaceuticals, Inc.

2200234(06-01)-2021-06-0802

SMART ALTERNATIVES

Paddock
Laboratories, Inc.

Please help us to minimize our printing costs. Call us at 1-800-545-3286 if you do not wish to receive any future issues of *Ichthyosis Focus*. **Help F.I.R.S.T. reduce its postage costs – would you be willing to accept the Focus Newsletter via e-mail? Let us know.**



F.I.R.S.T.
650 Cannon Ave.
Suite 17
Lansdale, PA 19446

PRSTD
FIRST CLASS
U.S. POSTAGE
PAID
PERMIT #2
COLMAR, PA